CancerVAX
A Breakthrough Universal Cancer Vaccine
Overview
Raised: $833,264
Total Commitments ($USD)
StartEngine
05/29/2023
Not Provided
$500
Equity - Common
Series A
RegA+
$2.00
$61,020,000
Rolling Commitments ($USD)
12/02/2023
$4,578
657
2021
Healthcare & Pharmaceuticals
Biotech
B2B2C
Medium
High
Balance Sheet
|
Cash and Cash Equivalents |
$602,748 |
|
Investment Securities |
$0 |
|
Total Investments |
$0 |
|
Accounts and Notes Receivable |
$0 |
|
Loans |
$0 |
|
Property, Plant and Equipment (PP&E) |
$2,433 |
|
Property and Equipment |
$0 |
| Total Assets |
$624,039 |
|
Accounts Payable & Accrued Liabilities |
$11,890 |
|
Policy Liabilities and Accruals |
$0 |
|
Deposits |
$0 |
|
Long Term Debt |
$2,000,000 |
|
Total Liabilities |
$11,890 |
|
Total Stockholders' Equity |
$-1,387,851 |
| Total Liabilities and Equity |
$624,039 |
Statement of Comprehensive Income Information
|
Total Revenues |
$0 |
|
Total Interest Income |
$0 |
|
Costs & Expenses Applicable to Rev |
$-689,624 |
|
Total Interest Expenses |
$0 |
|
Depreciation and Amortization |
$546 |
| Net Income |
$-689,624 |
|
Earnings Per Share - Basic |
$-6.13 |
|
Earnings Per Share - Diluted |
$-6.13 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
